Skip to content

Safety & efficacy assessment of products on skin.

To evaluate the safety and efficacy of skin care regime with combination of Bristaa Intense Cream and Photostable Gold Sunscreen Gel in female subjects with melasma and dark spots. - N/AP

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/11/038345
Enrollment
124
Registered
2021-11-30
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: ï?® Bristaa Intense Cream : Product A ï?® Photostable Gold Sunscreen Gel : Product B : For Product A (Bristaa Intense Cream): Approx. 1.0 gm quantity of given product will be appl

Sponsors

Sun Pharmaceutical Industries Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Having Fitz Patrick Skin type III-IV 2 Having dark spots on face (with at least one dark spot � 3.5mm in diameter) or having visible melasma on face (with mMASI score between 1-8) 3 Having dull skin (i.e., skin that lacks brightness & has uneven skin tone based on visual assessment by experts)

Exclusion criteria

Exclusion criteria: 1 Female who is pregnant or breastfeeding or has stopped breastfeeding in the past three months 2 Participating in another study liable to interfere with this study 3 Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area 4 Being insulin-dependent diabetic or non insulin-dependent diabetic with a recent therapy (less than 6 months) 5 Having progressive asthma Being epileptic Having non stabilized thyroid problems Having cutaneous hypersensitivity Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products or food products or to latex Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol) for more than 1 year. Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months. Having changed her cosmetic habits in the 14 days preceding the start of the study on the studied anatomic unit Having applied a cosmetic product (included make-up) on the studied areas the first day of the study (only face cleaned with water is accepted) Having started, changed or stopped a hormonal treatment (hormonal contraception, Hormone Replacement Therapy) in the past 3 months For Smokers - Any change in smoking habits as below - A person who was a non-smoker but has now started smoking >10 cigarettes per day in the last 6 months - A person who was smoking 10 cigarettes per day in the last 6 months - A person who was smoking >10 cigarettes per day but has now either stopped smoking or is smoking Having taken a medicinal treatment which could lead to hyper pigmentation (e.g. phenyto�¯n, amiodarone, metals, minocycline) in the previous 6 months Taking oral supplements or topical application with major or minor effect on whitening of skin (e.g. vitamin C, beta-carotene) Having applied beauty treatment (e.g. skin cleansing, exfoliation, scrub, mask) or self-tanning products in the week preceding the start of the study Having applied products with anti-wrinkle action (e.g. retinoic acid, retinol, retinaldehyde, isotretinoin, A.H.A.) in the 2 weeks preceding the start of the study Having applied products with a depigmenting action (e.g. hydroquinone or derivates) in the 4 weeks preceding the start of the study Having undergone physical and/or chemical treatments of the spots (e.g. liquid nitrogen, dry ice, pulsed flash lamp, dermabrasion, chemical peel) in the previous 6 months Having a suntanned skin on the studied areas which could interfere with the evaluations of the study Have taken any other treatment that in the opinion of the investigator could interfere with the evaluations of the study

Design outcomes

Primary

MeasureTime frame
Safety & Efficacy assessment of productsTimepoint: Screening T0, T28 days , T42 days T56 days, T70 days and T90 days

Secondary

MeasureTime frame
Not ApplicableTimepoint: Not Applicable

Countries

India

Contacts

Public ContactMr Mohit Lalvani

Mascot Spincontrol India Pvt. Ltd.

raji@mascotspincontrol.in022-43349191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026